Prerpints.org logo
Preprint
Article

This version is not peer-reviewed.

The Impact of Antibiotic Prophylaxis in a Retrospective Cohort of Hospitalized Patients with COVID-19 Treated with the Combination of Steroids and Tocilizumab

A peer-reviewed article of this preprint also exists.

Submitted:

25 September 2023

Posted:

29 September 2023

You are already at the latest version

Preprints on COVID-19 and SARS-CoV-2
Abstract
Objectives: In the context of COVID-19, patients with severe or critical illness may be more susceptible to developing secondary bacterial infections. This study aims to investigate the relationship between the use of prophylactic antibiotic therapy and the occurrence of bacterial or fungal isolates following the administration of tocilizumab in hospitalized COVID-19 patients who had previously received steroids during the first and second waves of the pandemic in Spain. Methods: This retrospective observational study included 70 patients hospitalized with COVID-19 who received tocilizumab and steroids between January and December 2020. Data on demographics, comorbidities, laboratory tests, microbiologic results, treatment, and outcomes were collected from electronic health records. Patients were divided into two groups based on the use of antibiotic prophylaxis, and the incidence of bacterial and fungal colonizations/infections was analyzed. Results: Among the included patients, 45 patients received antibiotic prophylaxis. No significant clinical differences were observed between patients based on prophylaxis use regarding the number of clinically diagnosed infections, ICU admissions, or mortality rates. However, patients who received antibiotic prophylaxis showed a higher incidence of colonization by multidrug-resistant germs compared to the subgroup that did not receive prophylaxis. The most commonly isolated microorganisms were Candida albicans, Enterococcus faecalis, Staphylococcus aureus, and Staphylococcus epidermidis. Conclusions: In this cohort of hospitalized COVID-19 patients treated with tocilizumab and steroids, the use of antibiotic prophylaxis did not reduce the incidence of secondary bacterial infections. However, it was associated with an increased incidence of colonization by multidrug-resistant organisms.
Keywords: 
COVID-19
;  
Steroids
;  
Tocilizumab
;  
Prophylaxis
;  
Ceftobiprole
Subject: 
Medicine and Pharmacology  -   Epidemiology and Infectious Diseases

INTRODUCTION

In the context of COVID-19, patients with severe or critical illness may be more susceptible to developing secondary bacterial infections. Several meta-analysis studies have found a prevalence of bacterial coinfection in hospitalized patients ranging from 3.5% to 12% (1)(2). The risk of coinfection increases in patients requiring admission to critical care units, reaching up to 14%-23% (2)(3). In most published observational studies and systematic reviews, the timing of bacterial infection diagnosis is not reported, so the term "coinfection" does not discriminate between community-acquired or nosocomial acquisition in these studies. However, in a study that has taken into account the time since admission (4) they have found percentages of nosocomial bacterial superinfection similar to the rates published by studies that did not consider this factor.
The immunosuppressive treatment used for managing COVID-19 has been considered a potential risk factor for developing nosocomial acquired infections (5). In the current management of patients admitted with COVID-19, dexamethasone and tocilizumab guidelines have a strong recommendation level (6). The association of tocilizumab treatment with the occurrence of bacterial infections was previously known (7). The available data on the influence of tocilizumab on the risk of superinfection in COVID-19 to date are controversial. Stone et al (8) did not find a higher incidence of superinfections in patients treated with tocilizumab, but in their series, most of these patients did not receive steroids. In the cohort by Ripa et al (9), in the subgroup of patients who received immunosuppressive biological therapy, 14% presented at least one secondary infection compared to 9% of the overall population, with a median time from the start of therapy of 9 days; although in this cohort, only 22% of the included patients had received steroids. However, the meta-analysis by Tleyjeh IM. et al (10) and the series by Narain et al. (11) associate the use of the combination of tocilizumab and steroids with a higher incidence of superinfections. In the meta-analysis published by Peng et al., a significant increase in fungal infections was noted after the use of tocilizumab (12), although it was not associated with an increase in bacterial infections.
Given that there are no consistent data to support an appropriate recommendation regarding the use of antibiotics in patients without a clinically suspected or documented infection (6), antibiotic prophylaxis is not routinely recommended in hospitalized patients with COVID-19. However, it could be considered in patients with risk factors for secondary bacterial infections.
In this study, we examined the relationship between the use of prophylactic antibiotic therapy and bacterial or fungal isolates following the administration of tocilizumab in a cohort of hospitalized COVID-19 patients who had previously received steroids during the first and second waves of the pandemic in Spain.

METHODS

Study design and patients

This retrospective observational study was performed at the Hospital “Gómez Ulla” in Madrid (Spain), a 600-bed university centre that provides broad and specialized medical, surgical and intensive care for an urban population of 120,000 individuals. We included all patients of 14 years or older, hospitalized in the conventional ward and/or Intensive Care Unit (ICU) between 31 January and 6 December 2020 (first and second wave of the pandemic in Spain) with a clinical diagnosis of COVID-19 and confirmed by real-time reverse transcription PCR for SARS-CoV-2 in respiratory samples and who had received tocilizumab during hospitalization. The study was approved by the Ethics and Research Committee of the Study Hospital with code 25/20. Participants did not sign informed consent as it was a retrospective study, and there was no temporal overlap between their admission and data collection.

Data collection and outcomes

Using the off-guide drug dispensing software of the Hospital Pharmacy Service, the number of medical records of all patients who had been treated with at least one 400 mg dose of tocilizumab during the study period was obtained.
For all patients hospitalized with COVID-19 who met the inclusion criteria data concerning demographics (age, gender), epidemiology, comorbidities, laboratory tests, microbiologic results (blood and urine cultures, respiratory samples, urinary antigen tests and antimicrobial susceptibility), treatment and outcomes (intensive care unit admission, length of hospital stay and mortality) were collected directly from electronic health records and drug dispensing software.
The records of all patients with positive microbiologic results were reviewed by two clinics with specific training in infectious diseases researchers (MEM and JMN) to assess clinical significance. Microbiological isolates considered contaminants by microbiological or clinical criteria were excluded.

Procedures

Investigation of bacterial and fungal pathogens in blood, normally sterile fluids, sputum and other samples was performed with standard microbiologic procedures during hospitalization, as requested by the attending physician.
The samples were processed in the usual way in the laboratory following the procedures of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). The samples were seeded on bacteriologic media such as blood agar plate, chocolate agar plates and MacConkey agar plates using sterile wire loops and were incubated at 30 °C the filamentous fungi and 37 °C the yeasts for 48 hours in a thermostatic incubator. Routine fungus cultures were inoculated on Sabouraud/glucose (4 %). The plates were incubated at 37 °C. Subsequently the dominant and potentially pathogenic colonies were picked for bacterial and fungus detection using the VITEK MS system (bioMérieux, Marcy l’Étoile, France) or Microscan System (American MicroScan, Mahwah, N.J.). All these samples were processed according to the working procedures or processing samples published by the SEIMC (<seimcprocedimientomicrobiologia MUESTRAS RESPIRATORIAS.pdf> n.d.
Microbiological isolates within 14 days following the administration of tocilizumab were considered (13). Antibiotic prophylaxis was considered in patients who had received an antibiotic prescribed before or following the tocilizumab infusion with the aim of prophylaxis against bacterial superinfection. Concomitant treatment with steroids was considered in patients who had received before the tocilizumab infusion, at least one dose of dexamethasone equal to or greater than 6 mg/day or its equivalent. Coinfection was considered if the microbiological identification occurred within the first 48 hours of admission. Superinfection was considered if the isolate corresponded to a sample obtained at least 48 hours after hospital admission, and if, according to the clinical history data, there was clinical suspicion of infection prior to the communication of the isolate, and/or the responsible clinician had prescribed targeted antibiotic therapy against the isolated microorganism. The appearance of multidrug-resistant (MDR) bacteria was analyzed: carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and carbapenem-resistant Pseudomonas aeruginosa (CRPA).
The Charlson comorbidity index (14) and the SEIMC score (15) were calculated for all patients included. The Charlson index is a system for assessing ten-year life expectancy, depending on the age at which it is evaluated and the comorbidities of the subject. The SEIMC score is a prognostic scale developed by Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (Spanish Society of Infectious Diseases and Clinical Microbiology) that evaluates the risk of 30-day mortality based on parameters measured upon admission to the Emergency Department. The variables considered in this score are age, gender, the presence of dyspnea, baseline capillary oxygen saturation, the neutrophil-to-lymphocyte ratio, and creatinine clearance. A SEIMC score between 9-30 points is associated with a very high 30-day mortality risk.

Statistical analysis

Median and interquartile range were used for quantitative variables. Absolute frequencies and relative frequencies in percentages (%) were used for qualitative variables. Hypothesis testing was conducted using Fisher's exact. A p-value of less than 0.05 was considered statistically significant. Statistical analysis was performed using SPSS® version 25 software.

RESULTS

During the study period, a total of 2,069 COVID-19 patients were admitted to our hospital. Among these patients, 76 had a prescription for tocilizumab in the drug dispensation records of the Hospital Pharmacy Service. After reviewing the medical records, 6 patients who had not received the drug were excluded, resulting in a final study population of 70 patients (Figure 1).

Comorbidities and risk at admission

The 70 patients had a confirmed diagnosis of COVID-19 with a positive SARS-CoV-2 PCR test and were receiving steroid treatment at the time of tocilizumab administration. The median age was 66 years (IQR 54 - 77 years). The median Charlson index was 2 (IQR 2 - 5), and the median SEIMC score was 10 (interquartile range 5 - 15). Twenty patients (28.6%) required admission to the intensive care unit, and 32 (45.7%) died during hospitalization. All patients received tocilizumab either in the Emergency Department or on the general hospital ward. A total of 20 patients (28.5%) were subsequently admitted to the intensive care unit. The median number of days from tocilizumab administration to microbiological isolation was 8.
Forty-five patients (64.3%) received antibiotic prophylaxis. Age and SEIMC score at admission were analyzed, and no statistically significant differences were found in relation to receiving antibiotic prophylaxis. However, there was a tendency for patients who received antibiotic prophylaxis to have a higher Charlson index (Charlson subgroup with prophylaxis 3, subgroup without prophylaxis 2, p=0.09, Table 1).
A 24.4% of patients who received antibiotic prophylaxis ended up being admitted to the intensive care unit compared to 36% of patients who did not receive prophylaxis. However, no statistically significant differences were found. There were also no statistically significant differences in mortality between the two subgroups (Table 1).

Prophylaxis used and microbiological results

Fourteen out of the seventy patients who received tocilizumab were identified to have bacterial and/or fungal infection/colonization within 14 days after tocilizumab administration. Thirteen out of the fourteen patients were admitted to the ICU after administration (patient 12 did not enter the ICU), hence the sample collection was conducted during their ICU stay, see Table 3. Out of the 45 patients who received prophylaxis, 10 patients (22%) had significant microbiological isolates interpreted as colonization or infection. Out of the 25 patients who did not receive prophylaxis, 4 patients (16%) had significant microbiological isolates (Table 1). The most commonly used antibiotic prophylaxis were ceftriaxone and ceftobiprole. Other antibiotics used alone or in combination included piperacillin plus tazobactam, teicoplanin, meropenem, linezolid, ciprofloxacin, amoxicillin plus clavulanic acid, and cefepime. Subgroups with the two most commonly used prophylaxes, ceftriaxone and ceftobiprole, were analyzed independently (Table 2). No patient had a documented coinfection or superinfection prior to the administration of tocilizumab.
The most frequently isolated microorganisms were Candida albicans (n=7), P. aeruginosa (n=3), ESBL Escherichia coli (n=3), Enterococcus faecalis (n=3), Staphylococcus aureus (n=3), and Staphylococcus epidermidis (n= 2). Of the 18 samples with bacterial isolations, 4 samples (22%) presented a multidrug-resistant pathogen (3 ESBL E. coli, 1 MRSA). The four isolates with growth of multidrug-resistant bacteria were interpreted as colonization. The four samples were identified in four patients who had received antibiotic prophylaxis. In three out of the four patients, samples were collected during their ICU stay (patients 1, 8, and 9).
No statistically significant differences were found in isolates, colonization, ICU admissions, or mortality among the different studied prophylaxis groups.
Below, we describe the details of the patients who had microbiological isolations:
Patient 1. 53-year-old male. Charlson 3. SEIMC score 5. Prophylaxis with ceftriaxone, lasting for 6 days. Admitted to the ICU 4 days after tocilizumab administration. During their stay in the ICU, bacteremia due to S. epidermidis is observed, and C. albicans is isolated in bronchoaspirate and endotracheal aspirate samples. Additionally, positive IgM for Chlamydia pneumoniae is detected. The attending clinicians decided to treat the fungal isolation with intravenous anidulafungin, in addition to combined antibiotic coverage for the rest of the microbiological isolates. On day 12 after tocilizumab administration, ESBL E. coli is isolated in a rectal swab, which is interpreted as colonization. The patient dies after 35 days of ICU admission.
Patient 2. A 64-year-old male. Charlson 2. SEIMC Score 6. He received prophylaxis with ceftriaxone for 6 days. The day after the administration of tocilizumab, he was admitted to the ICU, and a urine culture was collected upon admission, which yielded E. faecalis, considered as a superinfection. Twelve days after tocilizumab administration, Klebsiella pneumoniae was isolated in blood cultures. The patient had a favorable outcome and was discharged from the hospital.
Patient 3: A 70-year-old woman. Charlson 5. SEIMC Score 8. Prophylaxis with ceftriaxone, which was maintained for 7 days. Admitted to the intensive care unit the following day. Five days after tocilizumab administration, C. albicans was isolated in a urine culture, which was treated with fluconazole, and ESBL E. coli was isolated in a rectal swab, considered as colonization. The patient had a favorable outcome and was discharged from the hospital.
Patient 4. Woman of 50 years old. Charlson 1. SEIMC Score 4. Prophylaxis with ceftriaxone for 6 days. Admitted to the intensive care unit on the same day as the administration of tocilizumab. On the 2nd day of ICU admission, C. albicans was isolated in a tracheal aspirate, leading to the initiation of fluconazole treatment, later switched to anidulafungin. On the 7th day of ICU admission, in the context of fever and clinical deterioration, several microbiological samples were collected, intravenous ceftriaxone was discontinued, and broad-spectrum antibiotic therapy was expanded, but there was no clinical improvement. The patient passed away before the growth result of E. faecalis in the urine culture was known.
Patient 5. A 73-year-old male. Charlson 3. SEIMC Score 6. Prophylaxis with ceftriaxone for 7 days. Admitted to the intensive care unit on the fourth day after the administration of tocilizumab. On the sixth day after tocilizumab administration, MRSA was isolated from the nasal swab, interpreted as colonization. The patient did not survive the intensive care unit admission.
Patient 6. A 45-year-old woman. Charlson 0. SEIMC Score 3. Prophylaxis with ceftobiprole, maintained for 6 days. Admitted to the intensive care unit on the day following the administration of tocilizumab. On the 6th day after tocilizumab administration, C. albicans was isolated in a urine culture, which was interpreted as a superinfection and treated with intravenous anidulafungin. Subsequent progress was satisfactory, and she was able to be discharged from the hospital after an extended admission.
Patient 7: 42-year-old female. Charlson 2. SEIMC Score 5. Prophylaxis with continuous infusion of ceftobiprole for one day. Admitted to the intensive care unit four days after tocilizumab administration. On the 7th day after tocilizumab administration, P. aeruginosa was isolated from bronchial aspirate sample. This was interpreted as colonization. The patient passed away in the intensive care unit.
Patient 8. 62-year-old male. Charlson 2. SEIMC Score 9. Prophylaxis with meropenem plus linezolid for 3 days. Admitted to the intensive care unit two days after tocilizumab administration. On the 14th day after tocilizumab administration, MRSA was isolated from nasal swab. This was interpreted as colonization. The patient survived the hospital admission and was discharged.
Patient 9. 70-year-old male. Charlson 4. SEIMC Score 9. Prophylaxis with meropenem plus linezolid for 12 days. Tocilizumab was administered on the third day of ICU admission. On the third day after tocilizumab administration, P. aeruginosa was isolated from rectal exudate in the context of clinical symptoms including fever, elevated inflammatory markers, and diarrhea, which was considered a superinfection. On the 14th day, an ESBL E.coli was isolated from rectal exudate, interpreted as colonization. The patient passed away in the intensive care unit.
Patient 10: 60-year-old male. Charlson 3. SEIMC Score 6. Prophylaxis with piperacillin plus tazobactam started on the day of tocilizumab administration, for one day. The patient was admitted to the intensive care unit the day after administration. On the 4th day, in the context of suspected respiratory superinfection, IgM serology for Mycoplasma pneumoniae came back positive, interpreted as superinfection. On the 6th day after tocilizumab administration, Aspergillus fumigatus was isolated in a bronchial aspirate sample, interpreted as superinfection. The patient passed away in the intensive care unit.
Patient 11. A 70-year-old woman. Charlson 3. SEIMC Score 10. She did not receive antibiotic prophylaxis. The patient was admitted to the intensive care unit on the fifth day after tocilizumab administration. On the day following admission to the ICU, Enterobacter sakazakii was isolated from a tracheal aspirate, interpreted as a superinfection, and intravenous antibiotic therapy was initiated. Eight days after admission to the ICU, C. albicans was isolated in a urine culture, and fluconazole was added to the treatment. On the 14th day following tocilizumab administration, C. albicans was isolated again from a tracheal aspirate, leading to a change in treatment to anidulafungin and voriconazole. The patient subsequently passed away in the ICU.
Patient 12. 77-year-old female. Charlson 3. SEIMC Score 14. She did not receive prior or simultaneous antibiotic prophylaxis with tocilizumab administration. On the 13th day after tocilizumab administration, S. epidermidis was isolated in blood cultures, and E. faecalis was isolated in a urine culture, with both isolations interpreted as superinfections. The patient passed away during the hospitalization.
Patient 13. 55-year-old male. Charlson 1. SEIMC Score 6. He did not receive prior or simultaneous antibiotic prophylaxis with tocilizumab administration. Admitted to the intensive care unit on the same day as tocilizumab administration. On the 13th day after tocilizumab administration, P. aeruginosa and C. albicans were isolated from a bronchial aspirate sample, interpreted as colonization. The patient survived the hospitalization and was discharged.
Patient 14. An 82-year-old male. Charlson 5. SEIMC Score 20. He did not receive prior or simultaneous antibiotic prophylaxis with tocilizumab administration. On the 7th day after tocilizumab administration, S. aureus was isolated in blood cultures and he admitted to the intensive care unit. The patient passed away in the intensive care unit

DISCUSSION

In this study, we describe the incidence and microbiological characteristics of bacterial and fungal colonizations/infections identified in patients hospitalized for COVID-19 and treated with steroids, following tocilizumab treatment, based on the use of antibiotic prophylaxis. In our cohort, 60.3% of the patients received antibiotic prophylaxis, mainly with ceftriaxone and ceftobiprole. There were no significant clinical differences between patients based on the use of prophylaxis, with a trend towards a higher number of comorbidities in the subgroup that received antibiotic prophylaxis. There were no significant differences between the two patient subgroups regarding the number of clinically diagnosed infections. However, in almost half of the patients who received antibiotic prophylaxis, colonization by a multidrug-resistant pathogen was identified, compared to no isolation with growth of a multidrug-resistant pathogen in the subgroup that did not receive antibiotic prophylaxis.
This work, to our knowledge, represents the first published study on the effects of prior antibiotic therapy before the administration of the combination of tocilizumab and steroids in COVID-19 patients, aiming to prevent the development of clinical infections or promote colonization. One of the likely reasons for the lack of literature on this topic is the difficulty in obtaining a significant number of patients, as evidenced in this study, where only 3.4% of the patients admitted during the study period met the inclusion criteria. 64.3% of the included patients received prophylaxis, with 11 different antibiotics, some of them in variable combinations, making it difficult to draw statistically significant differences. However, precisely because of the difficulty and lack of published data on this clinical question that arises in the daily practice of infectious disease units and intensive care units worldwide, the analysis of this cohort is relevant for two reasons. First, to attempt to draw conclusions that help discern the approach to prescribing antibiotic therapy or not in these patients. Second, to serve as a basis and stimulus for scientific societies and international study groups to analyze existing multicenter cohorts of COVID-19 patients, in search of a larger number of patients to identify statistically significant trends.
The authors are aware that these data correspond to COVID-19 patients diagnosed in Spain in 2020, and that there could be changes in these results following the emergence of subsequent variants of COVID-19 with different clinical courses. Similarly, the effects of vaccination could impact these results. Nevertheless, the current number of patients with moderate or severe COVID-19 eligible for tocilizumab treatment is very low, which explains the absence of further studies related to this topic.
Possible biases and confounding factors are also presented. Bacterial superinfections might be underdiagnosed for several reasons: difficulties in sample collection due to overwhelming hospital services during the first wave of the pandemic (16), a high number of bacterial pneumonias where microbiological diagnosis is not achieved, as is well-known in routine clinical practice (17)(18), and the non-use of PCR diagnostic techniques for bacterial identification in the analyzed samples. Another potential limitation of the study, given its observational nature, is that the risk of developing an infection might have been higher in the group of patients who received prophylaxis, and therefore, despite finding similar results between the two patient subgroups, this could be interpreted as a protective role of antibiotic prophylaxis. Interestingly, although not reaching statistically significant differences, the group of patients who received antibiotic prophylaxis showed a significant trend towards having more pre-existing comorbidities before the onset of the clinical condition (14)(19). Since the median comorbidity score was higher for the group with the antibiotic prophylaxis, without propensity scoring the comparison between cases and control may not be accurate. It could be that this group is sicker and that it in the past they have needed more antibiotics which leads to development of MDR bacteria. (5)
The 14% of tablea bacterial and/or fungal superinfection, without observing differences based on whether they had received antibiotic prophylaxis or not. In the retrospective cohort of hospitalized patients with COVID-19 published by Moreno et al. (20), where 82 out of 306 patients included were treated with tocilizumab, 14% of the patients experienced a severe infection, and 26% in those admitted to the ICU. However, in this cohort, there was no differentiation in the incidence of infections based on whether tocilizumab had been administered. In this study, it is not indicated whether the patients received antibiotic prophylaxis. However, 76.6% of the patients treated with tocilizumab received azithromycin for the treatment of COVID pneumonia.
In our study, the 40% of patients who received prophylaxis were treated with ceftriaxone, and 31.3% with ceftobiprole, allowing for some consequential case description. This is particularly important as these are two antimicrobials with different, and in the case of ceftobiprole, broader spectrum of action. Patients who received prophylaxis with ceftriaxone had a higher incidence of superinfection (22.2%) compared to the subgroup of patients who received prophylaxis with ceftobiprole (7.1%), and to the subgroup that did not receive prophylaxis (12%). We could infer that an ineffective empirical antibiotic therapy, without coverage of some bacteria that most frequently superinfect immunosuppressed COVID-19 patients (MRSA, Pseudomonas, E. faecalis) (4)(21)(22)(23), could alter the patients' commensal flora, thereby creating an ecological niche for these pathogens to subsequently infect patients more easily than would have occurred without unnecessary prior antibiotic therapy. This would explain cases like that of patient 1, with up to four isolations, where three of them could be interpreted as colonization, detected within 14 days after tocilizumab infusion. In fact, in this study, we did not find any superinfections caused by S. pneumoniae, despite it being another of the most frequently identified bacteria causing superinfections in COVID-19 (4)(21)(22)(23). When comparing the most frequently bacterial isolates in our patient cohort, urinary infection due to E. faecalis stands out in 3 patients, 2 of whom received ceftriaxone as prophylaxis. In the García-Vidal et al.(4) cohort, there were only two cases of urinary superinfection caused by E. faecalis out of the 74 documented bacterial infections; it's possible that the use of ceftriaxone may have contributed to the higher incidence of this microorganism in our study.
Reviewing the patients who received other antibiotic therapies, the isolations detected in patients treated with the combination of meropenem and linezolid (patients 8 and 9) are striking. Despite these patients receiving prophylaxis that, in theory, should have eliminated non-multidrug-resistant P. aeruginosa as in the case of meropenem (24)(25), and MRSA, including linezolid (26), a colonization by MRSA (patient 8) and a superinfection by P. aeruginosa were detected. In patients treated with ceftobiprole, no isolates of bacteria included in its microbiological coverage were identified. In the group of patients who received prophylaxis with ceftriaxone, only one patient presented a microbiological isolate that was initially covered by the bacterial spectrum of the chosen antibiotic prophylaxis (patient 4, bacteremia caused by ceftriaxone-sensitive K. pneumoniae).
In our study, the percentage of superinfections caused by multi-drug resistant bacteria is similar to what has been reported in other series (27)(28)(4). However, it's noteworthy that there were no occurrences of colonization/superinfections by carbapenem-resistant gram-negative bacteria, nor the isolation of Acinetobacter spp. This is in contrast to the increased prevalence of these during the COVID-19 epidemic as reported in several studies (28)(27). Mady et al. (29) evaluated the use of tocilizumab in patients with severe COVID-19 pneumonia requiring ICU admission. All patients included in this series were also given intravenous dexamethasone and prophylactic antibiotics (azithromycin, meropenem, vancomycin or piperacillin/tazobactam for 14 days). Twelve out of the 61 patients included (19%) developed a superinfection. The most frequent microorganisms were Acinetobacter baumanii and Pseudomonas spp. The local ecology of our hospital and limited use of meropenem as prophylaxis might account for our findings. On the other hand, our study highlights the isolation of ESBL E. coli in rectal swabs from three patients. This finding contrasts with the results of the systematic review published by Abubakar et al.(30). In this meta-analysis, they found a reduction in the prevalence of ESBL E. coli infections during the pandemic, which could be attributed to infection control strategies. In our case, the predominant use of cephalosporins as antibiotic prophylaxis could explain the increase in this pathogen.
Regarding fungal infections, in our study it is noTable that C. albicans was the most frequently isolated microorganism, found in 6 patients. One patient had an isolation of C. albicans in urine and another isolation in a tracheal aspirate sample. All patients with C. albicans isolation were admitted to the ICU after the administration of tocilizumab. In three patients, it was identified in respiratory tract samples, and in three patients, it was detected in urine cultures (Table 3). The interpretation of the colonization or pathogenic role of C. albicans isolates in respiratory samples from critically ill patients is highly debated, given the challenge of obtaining lung biopsies to confirm the presence of C. albicans in pulmonary parenchyma associated with inflammation. In general, the isolation of C. albicans in lower respiratory tract samples is interpreted as colonization, considering the rarity of pulmonary candidiasis (31). In all patients in whom C. albicans was isolated in both respiratory and urine cultures, clinicians made the decision to add antifungal treatment. However, the authors of this article have chosen to classify isolations from respiratory samples as colonizations. Nevertheless, this decision may be subject to questioning. The treatment with tocilizumab combined with systemic steroids has been shown to be a risk factor for the acquisition of Candida spp. in COVID-19 patients(32). Experimental studies performed in mice deficient in interleukin-6 have demonstrated the role of this interleukin in the defense against Candida infections (33)(34). The microbiological results of our cohort of patients treated with tocilizumab support these experimental studies. It would be of great interest to conduct clinical studies to assess whether antifungal prophylaxis prior to tocilizumab treatment would prevent these Candida colonizations/infections.
In conclusion, in our cohort of patients hospitalized for COVID-19, treated with steroids, and receiving tocilizumab, the use of antibiotic prophylaxis did not reduce the incidence of secondary bacterial infections. However, after the administration of prophylaxis, patients showed an increase in the incidence of colonization by multidrug-resistant bacteria.

Transparency Declaration

Authors report no conflicts of interest relevant to this editorial.

Statement

These results were partially presented at IdWeek 2021

References

  1. Calderon M, Gysin G, Gujjar A, McMaster A, King L, Comandé D, et al. Bacterial co-infection and antibiotic stewardship in patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 9 de enero de 2023;23(1):14.
  2. Soltani S, Faramarzi S, Zandi M, Shahbahrami R, Jafarpour A, Akhavan Rezayat S, et al. Bacterial coinfection among coronavirus disease 2019 patient groups: an updated systematic review and meta-analysis. New Microbes New Infect. septiembre de 2021;43:100910.
  3. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. agosto de 2020;81(2):266-75.
  4. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. enero de 2021;27(1):83-8.
  5. Bardi T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, Azzam Lopez A, Diez-Remesal Y, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. marzo de 2021;40(3):495-502.
  6. Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, et al. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. febrero de 2022;28(2):222-38.
  7. Morel J, Constantin A, Baron G, Dernis E, Flipo RM, Rist S, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatol Oxf Engl. 1 de octubre de 2017;56(10):1746-54.
  8. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 10 de diciembre de 2020;383(24):2333-44.
  9. Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. marzo de 2021;27(3):451-7.
  10. Tleyjeh IM, Kashour Z, Damlaj M, Riaz M, Tlayjeh H, Altannir M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. febrero de 2021;27(2):215-27.
  11. Narain S, Stefanov DG, Chau AS, Weber AG, Marder G, Kaplan B, et al. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm. Chest. marzo de 2021;159(3):933-48.
  12. Peng J, Fu M, Mei H, Zheng H, Liang G, She X, et al. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis. Rev Med Virol. mayo de 2022;32(3):e2295.
  13. Shikongo A, Nuugulu SM, Elago D, Salom AT, Owolabi KM. Fractional Derivative Operator on Quarantine and Isolation Principle for COVID-19. En: Advanced Numerical Methods for Differential Equations [Internet]. 1.a ed. Boca Raton: CRC Press; 2021 [citado 20 de septiembre de 2023]. p. 205-26. Disponible en: https://www.taylorfrancis.com/books/9781003097938/chapters/10. 1201/9781003097938-9.
  14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
  15. Berenguer J, Borobia AM, Ryan P, Rodríguez-Baño J, Bellón JM, Jarrín I, et al. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax. septiembre de 2021;76(9):920-9.
  16. Condes E, Arribas JR, COVID19 MADRID-S.P.P.M. group. Impact of COVID-19 on Madrid hospital system. Enfermedades Infecc Microbiol Clin Engl Ed. mayo de 2021;39(5):256-7.
  17. Burman LA, Trollfors B, Andersson B, Henrichsen J, Juto P, Kallings I, et al. Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens. J Infect Dis. mayo de 1991;163(5):1087-93.
  18. Reimer LG, Carroll KC. Role of the microbiology laboratory in the diagnosis of lower respiratory tract infections. Clin Infect Dis Off Publ Infect Dis Soc Am. marzo de 1998;26(3):742-8.
  19. Vaquero-Herrero MP, Ragozzino S, Castaño-Romero F, Siller-Ruiz M, Sánchez González R, García-Sánchez JE, et al. The Pitt Bacteremia Score, Charlson Comorbidity Index and Chronic Disease Score are useful tools for the prediction of mortality in patients with Candida bloodstream infection. Mycoses. octubre de 2017;60(10):676-85.
  20. Moreno-Pérez O, Andres M, Leon-Ramirez JM, Sánchez-Payá J, Rodríguez JC, Sánchez R, et al. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. J Autoimmun. noviembre de 2020;114:102523.
  21. Westblade LF, Simon MS, Satlin MJ. Bacterial Coinfections in Coronavirus Disease 2019. Trends Microbiol. octubre de 2021;29(10):930-41.
  22. Puzniak L, Finelli L, Yu KC, Bauer KA, Moise P, De Anda C, et al. A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19. BMC Infect Dis. 27 de febrero de 2021;21(1):227.
  23. Zamora-Cintas MI, López DJ, Blanco AC, Rodriguez TM, Segarra JM, Novales JM, et al. Coinfections among hospitalized patients with covid-19 in the first pandemic wave. Diagn Microbiol Infect Dis. noviembre de 2021;101(3):115416.
  24. Unal S, Garcia-Rodriguez JA. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis. diciembre de 2005;53(4):265-71.
  25. Linden, P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf. 2007;30(8):657-68.
  26. Bouza E, Muñoz P. Linezolid: pharmacokinetic characteristics and clinical studies. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2001;7 Suppl 4:75-82.
  27. Kariyawasam RM, Julien DA, Jelinski DC, Larose SL, Rennert-May E, Conly JM, et al. Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019-June 2021). Antimicrob Resist Infect Control. 7 de marzo de 2022;11(1):45.
  28. Lai CC, Chen SY, Ko WC, Hsueh PR. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents. abril de 2021;57(4):106324.
  29. Mady A, Aletreby W, Abdulrahman B, Lhmdi M, Noor AM, Alqahtani SA, et al. Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series. Ann Med Surg 2012. diciembre de 2020;60:417-24.
  30. Abubakar U, Al-Anazi M, Alanazi Z, Rodríguez-Baño J. Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: A systematic review. J Infect Public Health. marzo de 2023;16(3):320-31.
  31. Meena DS, Kumar D. Candida Pneumonia: An Innocent Bystander or a Silent Killer? Med Princ Pract Int J Kuwait Univ Health Sci Cent. 2022;31(1):98-102.
  32. Segrelles-Calvo G, de S Araújo GR, Llopis-Pastor E, Carrillo J, Hernández-Hernández M, Rey L, et al. Candida spp. co-infection in COVID-19 patients with severe pneumonia: Prevalence study and associated risk factors. Respir Med. noviembre de 2021;188:106619.
  33. Romani L, Mencacci A, Cenci E, Spaccapelo R, Toniatti C, Puccetti P, et al. Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med. 1 de abril de 1996;183(4):1345-55.
  34. van Enckevort FH, Netea MG, Hermus AR, Sweep CG, Meis JF, Van der Meer JW, et al. Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice. Med Mycol. diciembre de 1999;37(6):419-26.
Preprints 86128 g001
Figure 1. Flowchart of Patient Selection for the Study.
Figure 1. Flowchart of Patient Selection for the Study.
Preprints 86128 g001
Table 1. Characteristics of study population.
Table 1. Characteristics of study population.
Preprints 86128 i001
IQR: interquartile range. ICU: intensive care unit.
Table 2. Outcomes according to antimicrobial prophylaxis prior to tocilizumab.
Table 2. Outcomes according to antimicrobial prophylaxis prior to tocilizumab.
Preprints 86128 i002
Table 3. Description of microbiological isolates.
Table 3. Description of microbiological isolates.
Preprints 86128 i003
MRSA: methicillin resistant Staphylococcus aureus. ESBL: extended-spectrum β-lactamases.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
bsky
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2025 MDPI (Basel, Switzerland) unless otherwise stated